glp 1 agonists muscle loss Weight with GLP-1 medicines does not result in a disproportionate loss of mass or function in obese mice and humans: Cell Reports Medicine Future questions for GLP1 receptor

Unlike sarcopenia, which requires both loss of muscle quantity and reduced function, lean mass reduction is a body-composition outcome most often assessed using dual-energy X-ray absorptiometry (DXA) or bioimpedance analysis (BIA) [2, 20]

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 811 April 2024

Some studies have shown greater average weight loss with tirzepatide compared with semaglutide, but the best choice depends on the patients medical history, treatment goals, side-effect tolerance, metabolic risk, and physician evaluation

Its a question of time

Adverse effects included: Severe hypoglycaemia , acute pancreatitis and gastrointestinal side effects

Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia